Reference Materials for Analysis of BRCA1 and BRCA2 Gene Variants with Expansion to Large Genomic Rearrangements (LGRs) to Support Therapy Selection in Breast and Ovarian Cancer Patients
Accurate detection of BRCA1 or BRCA2 pathogenic variants are critical in breast and ovarian cancer therapy as well as clinical management of disease including patients who are eligible for new PARP inhibitors. To learn more, download our latest poster.
To download, fill out the form and you will receive an email with the content.
%20to%20Support%20Therapy%20Selection%20in%20Breast%20and%20Ovarian%20Cancer%20Patients.png?width=1420&height=826&name=Reference%20Materials%20for%20Analysis%20of%20BRCA1%20and%20BRCA2%20Gene%20Variants%20with%20Expansion%20to%20Large%20Genomic%20Re%20arrangements%20(LGRs)%20to%20Support%20Therapy%20Selection%20in%20Breast%20and%20Ovarian%20Cancer%20Patients.png "Reference Materials for Analysis of BRCA1 and BRCA2 Gene Variants")